Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907334 | 0.86 | SCN9A (0.34) | TSHRENPP2 | |
| SCHEMBL16532110 | 0.85 | SCN9A (0.35) | TSHRENPP2 | |
| SCHEMBL16532012 | 0.81 | SCN9A (0.38) | — | |
| SCHEMBL16531976 | 0.80 | SCN9A (0.34) | ENPP2 | |
| SCHEMBL17907293 | 0.78 | POLB (0.35) | — | |
| SCHEMBL17907302 | 0.75 | DGAT1 (0.46) | ENPP2 | |
| SCHEMBL17907311 | 0.74 | MAPT (0.37) | TSHRENPP2 | |
| SCHEMBL16531972 | 0.72 | P2RX3 (0.39) | TSHR | |
| SCHEMBL15521973 | 0.72 | AOC3 (0.50) | — | |
| SCHEMBL17907358 | 0.66 | DGAT1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | DGAT1, DGAT2, LCAT | TSHR 2794/4885ENPP2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.